
The regulator cited a lack of statistically significant overall survival benefit, while investors await data from a separate first-line lung cancer trial.
The US Food and Drug Administration declined to approve Summit Therapeutics’ experimental lung cancer drug ivonescimab. The agency cited a late-stage study that failed to show a statistically significant overall survival benefit.
Summit had sought approval for the drug with chemotherapy for previously treated patients with advanced non-squamous non-small cell lung cancer with EGFR mutations. The company later submitted longer follow-up results showing statistically significant overall survival, according to the report.
Summit shares were down 14% at $12.16 in morning trading, according to Reuters. As of 15:52 UTC, they traded at $12.38, down 12.51% from the previous close.
Investors are awaiting data later this year from a separate global late-stage trial comparing ivonescimab with Merck’s Keytruda as a first-line treatment.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.